HEPS vs LQDT

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.

LQDT demonstrates exceptional operational health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.06. However, the stock is currently trading at a premium ($32.60) relative to both its Graham Number ($12.03) and its Intrinsic Value ($27.14). While the company has an impressive track record of earnings beats and strong YoY earnings growth (27.8%), this is contrasted by stagnant revenue growth (-0.90%) and aggressive insider selling by the CEO and CFO. The disconnect between strong fundamental health and bearish insider/technical signals suggests the stock is currently overextended.